# Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

> **NCT03539055** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 100 (actual)

## Conditions studied

- Atrial Fibrillation
- Device Related Thrombus
- Left Atrial Appendage Thrombosis
- Watchman LAA Closure Device

## Interventions

- **DRUG:** Dabigatran Etexilate Oral Capsule

## Key facts

- **NCT ID:** NCT03539055
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-02-29
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539055, "Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03539055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*